Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 05 10; 34(14):1584-93.

View in: PubMed

subject areas

Adult
Androstadienes
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Estradiol
Estrogens
Estrone
Female
Follicle Stimulating Hormone
Humans
Luteinizing Hormone
Ovary
Tamoxifen
Triptorelin Pamoate

authors with profiles

Gini Fleming